These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9347896)

  • 1. Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein.
    Bain LJ; McLachlan JB; LeBlanc GA
    Environ Health Perspect; 1997 Aug; 105(8):812-8. PubMed ID: 9347896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
    Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
    ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein.
    Bain LJ; LeBlanc GA
    Toxicol Appl Pharmacol; 1996 Nov; 141(1):288-98. PubMed ID: 8917702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-Glycoprotein Transport of Neurotoxic Pesticides.
    Lacher SE; Skagen K; Veit J; Dalton R; Woodahl EL
    J Pharmacol Exp Ther; 2015 Oct; 355(1):99-107. PubMed ID: 26272936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
    Erić S; Kalinić M; Ilić K; Zloh M
    SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2.
    Zhou Y; Gottesman MM; Pastan I
    Arch Biochem Biophys; 1999 Jul; 367(1):74-80. PubMed ID: 10375401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evaluations of the P-glycoprotein-mediated efflux of dibenzoylhydrazines.
    Miyata K; Nakagawa Y; Kimura Y; Ueda K; Akamatsu M
    Toxicol Appl Pharmacol; 2016 May; 298():40-7. PubMed ID: 26995013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation and function of the multidrug resistance genes in liver.
    Silverman JA; Thorgeirsson SS
    Prog Liver Dis; 1995; 13():101-23. PubMed ID: 9224499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
    Tournier N; Valette H; Peyronneau MA; Saba W; Goutal S; Kuhnast B; Dollé F; Scherrmann JM; Cisternino S; Bottlaender M
    J Nucl Med; 2011 Mar; 52(3):415-23. PubMed ID: 21321274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.
    Stark M; Assaraf YG
    Oncotarget; 2017 Jul; 8(30):49973-49987. PubMed ID: 28637003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional role of the linker region in purified human P-glycoprotein.
    Sato T; Kodan A; Kimura Y; Ueda K; Nakatsu T; Kato H
    FEBS J; 2009 Jul; 276(13):3504-16. PubMed ID: 19490125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors.
    Wang RB; Kuo CL; Lien LL; Lien EJ
    J Clin Pharm Ther; 2003 Jun; 28(3):203-28. PubMed ID: 12795780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of multidrug resistance of tumor cells.
    Szabó D; Keyzer H; Kaiser HE; Molnár J
    Anticancer Res; 2000; 20(6B):4261-74. PubMed ID: 11205256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance.
    Battisti RF; Zhong Y; Fang L; Gibbs S; Shen J; Nadas J; Zhang G; Sun D
    Mol Pharm; 2007; 4(1):140-53. PubMed ID: 17274671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future directions for drug transporter modelling.
    Ekins S; Ecker GF; Chiba P; Swaan PW
    Xenobiotica; 2007; 37(10-11):1152-70. PubMed ID: 17968741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy.
    Silva R; Vilas-Boas V; Carmo H; Dinis-Oliveira RJ; Carvalho F; de Lourdes Bastos M; Remião F
    Pharmacol Ther; 2015 May; 149():1-123. PubMed ID: 25435018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of P-glycoprotein substrate and inhibition potential of test compounds in MDR1-transfected MDCK cells.
    C L Lam K; Rajaraman G
    Curr Protoc Pharmacol; 2012 Sep; Chapter 7():Unit7.13. PubMed ID: 22948850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.